RxDoctor Payments Data

Stanton Dodson, MD

Transplant Surgery · Boca Raton, FLNPI 1942238803

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (57.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 73.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $4,918 and has fallen 99.4% since, to $31 in 2025.

$6,981in general payments, 2019–2025

Across 23 payments — averaging $303.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Baxter Healthcare$2K
  • Johnson & Johnson$59
  • Boston Scientific$57
  • AbbVie$17
  • AstraZeneca$17
  • plus $14 from 1 others

What the payments were for

  • Consulting fees$1,57623%
  • Travel & lodging$79511%
  • Food & beverage$6099%
  • Education$4,00057%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,981 in reported general payments places this provider in the 65th percentile of 53 transplant surgery providers in Florida.

See all transplant surgery providers in Florida

Medicare billing

Part B allowed, 2024
$121,593
Medicare patients
144
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$31,826
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$127
Tramadol Hcl14$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$17$31,82611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 53 transplant surgery providers in Florida.

Other transplant surgery in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →